Skip to main content

Advertisement

Table 3 Characteristics of patients and survival analysis (by grade of DMVD)

From: Contrast enhanced computed tomography is indicative for angiogenesis pattern and display prognostic significance in breast cancer

Characteristic Uniform distribution (DMVD < 10) (n = 187) Uneven distribution (DMVD > 10) (68) Statistics P
Age (years) 51.86 ± 9.55 52.04 ± 9.84 -0.138 0.890
Menopause    0.389 0.572
Postmenopausal 88 35   
Premenopausal 99 33   
Family history    0.012 1.000
No 174 63   
Yes 13 5   
Diameter 2.21 ± 0.95 2.67 ± 1.31 -3.061 0.002
Quadrant    5.680 0.224
Areolar 3 2   
Inner upper 39 6   
Inner lower 17 8   
Outer lower 32 11   
Outer upper 96 41   
Patterns of enhancement    179.854 0.000
Homogeneous 77(41.2%) 5(7.4%)   
Heterogeneous 110(58.8%) 11(16.2%)   
Peripheral 0(0%) 52(76.5%)   
Difference of MVD (Edge - Center) 1.29 ± 5.03 15.60 ± 4.27 -20.873 0.000
Histological grade    2.105 0.349
I 50 13   
II 120 46   
III 17 9   
Cancer thrombosis    1.891 0.204
Negative 140 45   
Positive 47 23   
Nodal metastasis    0.174 0.777
Negative 88 30   
Positive 99 38   
Number of metastatic nodes 2.91 ± 5.97 6.21 ± 9.42 -3.302 0.001
Clinical stage    18.458 0.002
I 46(24.6%) 13(19.1%)   
IIA 60(32.1%) 16(23.5%)   
IIB 64(34.2%) 20(29.4%)   
IIIA 11(5.9%) 7(10.3%)   
IIIB 2(1.1%) 5(7.4%)   
IIIC 4(2.1%) 7(10.3%)   
IV 0(0%) 0(0%)   
ER    18.731 0.000
Negative 57(30.5%) 41(60.3%)   
Positive 130(69.5%) 27(39.7%)   
PgR    26.314 0.000
Negative 48(25.7%) 41(60.3%)   
Positive 139(74.3%) 27(39.7%)   
HER2    9.786 0.003
Negative 167(89.3%) 50(73.5%)   
Positive 20(10.7%) 18(26.5%)   
Ki67    10.827 0.001
Negative (<14%) 120(64.2%) 28(41.2%)   
Positive (>14%) 67(35.8%) 40(58.8%)   
P53 (%) 32.08 ± 31.58 29.90 ± 33.94 0.479 0.633
Clinicopathological subtypes    42.300 0.000
Luminal A 102(54.5%) 17(25.0%)   
Luminal B (Ki67+) 44(23.5%) 8(11.8%)   
Luminal B (HER2+) 14(7.5%) 8(11.8%)   
HER2 overexpression 6(3.2%) 10(14.7%)   
TNBC 21(11.2%) 25(36.8%)   
Operation    0.819 0.485
Mastectomy 166 63   
Tumorectomy 21 5   
Chemotherapy program    17.357 0.004
Not performed 0(0%) 2(2.9%)   
CMF 2(1.1%) 0(0%)   
CAF or AC 60(32.1%) 12(17.6%)   
CEF or EC 43(23.0%) 19(27.9%)   
T or TC or TP 59(31.6%) 17(25.0%)   
TAC or A-T 23(12.3%) 18(26.5%)   
Radiotherapy    2.012 0.160
Not performed 104 31   
Performed 83 37   
Endocrine therapy    38.443 0.000
Not performed 27(14.4%) 35(51.5%)   
TAM 99(52.9%) 20(29.4%)   
LHRH 13(7.0%) 5(7.4%)   
AI 48(25.7%) 8(11.8%)   
Targeted therapy    0.116 1.000
Not performed 183 67   
Performed 4 1   
Overall survival 99.5% 85.3% 24.308 0.000
Event 1 10   
Deaths 1 9   
Lost to Follow-up 0 1   
Median survival time 54.0 54.0 14.885 0.000
Disease-free survival 99.5% 67.6% 62.030 0.000
Event 1 22   
Local recurrence 0 1   
Contralateral breast cancer 0 4   
Lung metastasis 0 2   
Hepatic metastasis 0 5   
Brain metastasis 0 3   
Multi-organ 1 6   
Lost to Follow-up 0 1   
Disease-free survival 54.0 31.9 47.546 0.000
Follow-up time    0.384 0.701
Median 23.0 22.0   
Range 12-58 12-59